Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. The clinical trial, which will be the first-in-human study of Advaxis’s lead Lm-LLO immunotherapy product for HER2 expressing cancers, is expected to begin patient enrollment in the first half of 2015.On Friday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $7.73.
On 16 January Canadian Industry Minister James Moore said he has been assured by BlackBerry Ltd. (NASDAQ:BBRY) Chief Executive Officer John Chen that there’s no substance to reports that Samsung Electronics Co. had approached the company about an acquisition. BlackBerry Ltd (NASDAQ:BBRY) in last trading activity moved up 1.86% to close at $10.70. Company weekly performance is 5.89% while its quarterly performance stands at 8.24%. BlackBerry Ltd (NASDAQ:BBRY) is -15.24% away from its 52 week high.
Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, on 14 January announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Auspex’s investigational compound SD-809 for the treatment of Tourette syndrome in the pediatric population (defined as zero through 16 years of age). On last trading day Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) moved up 2.74% to close at $58.46. Its volatility for the week is 10.75% while volatility for the month is 7.36%. Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) monthly performance is 7.54%.
Research analysts at Jefferies Group boosted their price target on shares of Consumer Portfolio Services (NASDAQ:CPSS) from $9.00 to $10.00 in a report released on Friday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 35.87% from the stock’s previous close. Consumer Portfolio Services, Inc. (NASDAQ:CPSS) has 3.10% insider ownership while its institutional ownership stands at 57.20%. In last trading activity company’s stock closed at $6.04.
Skullcandy, Inc. (NASDAQ:SKUL) announced that the Company presented at the 17th Annual ICR XChange Conference at the JW Marriott Orlando Grande Lakes in Orlando, Florida on January 13, 2015. On last trading day Skullcandy, Inc. (NASDAQ:SKUL) moved up 1.97% to close at $10.37. Its volatility for the week is 2.88% while volatility for the month is 3.75%. SKUL’s sales growth for past 5 years was 21.20% and its EPS growth for past 5 years was -17.30%. Skullcandy, Inc. (NASDAQ:SKUL) monthly performance is 17.31%.